Search the Newsreel

Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales

Adaptive Biotechnologies (ADPT) stock appears fairly valued based on its discounted cash flow model, which places its intrinsic value close to its current share price. However, the stock looks expensive when evaluated using market multiples, particularly its P/S ratio, which is significantly higher than …

Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock

Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of …

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high …

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares

A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The …

Adaptive Biotechnologies (ADPT) Is Up 10.5% After Raising 2026 MRD Revenue Guidance Has The Bull Case Changed?

Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT

Renaissance Technologies LLC has acquired 239,800 shares of Adaptive Biotechnologies Corporation, valued at approximately $3.33 million, marking a new stake in the company. Institutional investors collectively hold 99.17% of Adaptive Biotechnologies. The company reported better-than-expected quarterly revenue but missed earnings estimates, while analysts maintain …

Adaptive Biotechnologies (ADPT) Stock Gains Little As MRD Growth Meets Wider Losses

ADAPTIVE BIOTECHNOLOGIES CORP : PIPER SANDLER RAISES TARGET PRICE TO $27.50 FROM $20.00

Piper Sandler has increased its target price for Adaptive Biotechnologies Corp to $27.50 from $20.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The information was reported by Reuters.

Adaptive Biotechnologies (NASDAQ: ADPT) raises $345M in 2031 notes

Adaptive Biotechnologies (ADPT) has issued $345 million in 0% convertible senior notes due 2031, using part of the proceeds to repurchase revenue interests and common stock. The company reported a Q2 2026 revenue of $71.6 million, an increase from the previous year, driven by …

Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary

Adaptive Biotechnologies Corp (ADPT) reported Q2 2026 financial results, with revenue reaching $71.6 million, an increase from $58.9 million in the previous year. The company recorded a net loss of $(39.8) million and a diluted loss per share of $(0.25). Key drivers included a …

Adaptive Biotechnologies CCO Susan Bobulsky sells $31,176 shares

Susan Bobulsky, CCO of Adaptive Biotechnologies (NASDAQ:ADPT), sold

Form 4 Adaptive Biotechnologies Corp For: 3 August By Investing.com

This article from Investing.com announces the filing of Form 4 for Adaptive Biotechnologies Corp on August 3rd. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol …

Adaptive Biotechnologies (NASDAQ: ADPT) CCO trades 1,299 shares under plan

Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 1,299 shares of common stock on July 30, 2026, at $24.00 per share, totaling $31,176. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, Bobulsky …

Adaptive Biotechnologies (ADPT) Raised MRD Guidance, Is The Stock Fairly Valued?

5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX

(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained long-term value, rather than chasing numerous average investments. …

Adaptive Biotechnologies Corporation Revenue Breakdown – NASDAQ:ADPT

Adaptive Biotechnologies Corp (ADPT) Shares Fall 6.7% -- GF Value Says Still Overvalued

Adaptive Biotechnologies Corp (ADPT) shares dropped 6.7%, and GuruFocus's GF Value suggests the stock is 125.0% overvalued at $22.57 compared to its estimated fair value of $10.03. Despite an above-average GF Score of 66/100, driven by strong growth and momentum ranks, its financial strength …

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 14.1% over the past month. The stock hit a new 52-week high of $24.34 in the previous session. Adaptive Biotechnologies has gained 48.9% since the start of the year compared …

Adaptive Biotechnologies Corp (ADPT) Institutional Confidence

The article discusses the institutional confidence score for Adaptive Biotechnologies Corp (ADPT), which is currently 10.00, ranking it 1st in the Biotechnology & Medical Research industry. Institutional shareholding stands at 94.68%, with a slight quarter-over-quarter decrease. Andreas Halvorsen is highlighted as the largest institutional …

Adaptive Biotechnologies (NASDAQ: ADPT) insider reports Rule 10b5-1 stock sales

Adaptive Biotechnologies insider Susan Bobulsky has filed planned stock sales under a Rule 10b5-1 trading plan. The Form 144 filing details multiple open-market sales of common shares on NASDAQ in June and July 2026, totaling 26,487 shares for proceeds of $521,214.00. The sales are …

Adaptive Biotechnologies Number of Employees 2026 | Employee Count & Headcount Data

Adaptive Biotechnologies (NASDAQ: ADPT) had approximately 632 employees worldwide as of March 2026, a decline of 18.7% from 777 employees in 2023. Despite the overall headcount decline, the company is actively hiring, with 53 active job postings in 2026, a 40.9% increase from 2025. …

Adaptive Biotechnologies stock hits 52-week high at 23.25 USD

Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $23.25, reflecting a significant 120.31% increase over the past year. Despite its robust revenue growth of 56% over the last twelve months, InvestingPro analytical data suggests the stock might be overvalued. Recent Q2 results showed …

Adaptive Biotechnologies Q2 Net Loss Widens Despite Revenue Growth; Stock Down

(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss amid revenue growth. In addition, the company also provided an update on its full-year 2026 revenue outlook for …

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

This article first appeared on GuruFocus. Total Revenue: $71.6 million, up 30% year-over-year. MRD Revenue: $66.2 million, up 33% year-over-year; core MRD revenue (excluding milestones) grew 49%. Clinical Revenue (MRD): Increased 53% year-over-year, driven by a 43% increase in testing volumes and a 7% …

Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Adaptive Biotechnologies Corp (AD

ETFs Investing in Adaptive Biotechnologies Corp. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (A2PLR5). It provides detailed financial data for each ETF, including market value, weight of Adaptive Biotechnologies stock, issuer, management style, focus, expense ratio, AUM, price change, and 3-year NAV …

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) reported $71.55 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 21.5%. EPS of -$0.10 for the same period compares to -$0.17 a year ago. The reported revenue represents a surprise of +7.98% over the Zacks …

Adaptive Biotechnologies (ADPT) Releases Q2 2026 Earnings: Revenue Growth but Still Unprofitable

Adaptive Biotechnologies (ADPT) reported Q2 2026 revenues of $71.6 million, marking a 21.5% year-over-year increase and surpassing analyst estimates. Despite this revenue growth and improved gross profit, the company remained unprofitable, posting a net loss of $39.8 million. Insider trading data shows significant sales …

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results …

Adaptive Biotechnologies' MRD Business Grew 33%; clonoSEQ Volume Reached 36,111

Adaptive Biotechnologies (ADPT) reported strong Q2 2026 financial results, with overall revenue up 22% to $71.6 million, largely driven by its Minimal Residual Disease (MRD) business, which grew 33% year-over-year. The company also announced plans to separate its MRD and Immune Medicine businesses, completed …